Zambon links with US WorldMeds to bring Xadago to the USA
Privately-held Italian drugmaker Zambonhas entered into a strategic agreement with US WorldMeds to commercialize fellow Italy-based Newron Pharmaceuticals’ (NWRN: SIX) lead compound, Xadago (safinamide), for the treatment of Parkinson’s disease in the USA. Newron’s shares gained 4.48% to 18.65 euros following the announcement this morning
Zambon holds the global marketing rights for safinamide with the exception of Japan/Asia and has recently begun the commercialization of safinamide under the trade name Xadago in the European Union and Switzerland.
“We are really pleased to have signed this agreement for Xadago with US WorldMeds” said Maurizio Castorina, chief executive of Zambon, adding: “It will help Zambon to fulfill the promise of bringing Xadago to patients with Parkinson’s disease in the United States and highlights once again our commitment to the CNS therapeutic area.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze